Mr Nicolas Legrand

Mr Nicolas Legrand

Research Officer

Master of International Public Health/Master of Public Health, The University of New South Wales

Bachelor of Arts and Science (Honours), The University of Sydney

Medicine & Health
The Kirby Institute

Nicolas is a PhD candidate and research officer in the Global Health Program, and the Surveillance Evaluation and Research Program. After five years of working in microbiology research and teaching at the University of Sydney, Nicolas completed a dual MIPH/MPH at UNSW specializing in Infectious Disease Epidemiology and Control. He then completed an internship with the World Health Organization in the Philippines focused on strengthening the national hepatitis B surveillance system. Nicolas works across a number of research projects at the Kirby Institute, which include producing epidemiological reports on the outbreak of infectious Syphilis among Aboriginal communities, enhancing the surveillance of HTLV-1 in Australia, and investigating outbreaks of COVID-19 in correctional facilities. He is also an investigator on an Australia-first longitudinal cohort study aimed at evaluating the impact of HTLV-1 infection on morbidity and mortality among remote Aboriginal communities in Central Australia. 

 

 

Publications

Legrand N, McGregor S, Bull R, Bajis S, Valencia BM, Ronnachit A, Einsiedel L, Gessain A, Kaldor J, Martinello M. Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection. Clin Microbiol Rev. 2022 Apr 20;35(2):e0007821. doi: 10.1128/cmr.00078-21. Epub 2022 Feb 23. PMID: 35195446; PMCID: PMC8941934.

Reports

Human T-lymphotropic virus type 1: technical report. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Phone
+61 2 9385 0988
  • Book Chapters | 2025
    Legrand N; Van Weyenbergh J; Kaldor J; Martin F, 2025, 'Human T-Lymphotropic Virus', in Principles and Practice of Infectious Diseases, Elsevier
  • Journal articles | 2025
    Legrand NM; Bull RA; Hajarizadeh B; Lloyd AR; Johnston K; Issa K; Harvey C; Arnott A; Dwyer DE; Sintchenko V; Grant L; Dore GJ; Kaldor J; Martinello M, 2025, 'Surveillance of Viral Respiratory Infections within Maximum-Security Prison, Australia', Emerging Infectious Diseases, 31, pp. 1527 - 1536, http://dx.doi.org/10.3201/eid3108.240571
    Journal articles | 2024
    Le B; Clarke NE; Legrand N; Nery SV, 2024, 'Effectiveness of ivermectin mass drug administration in the control of soil-transmitted helminth infections in endemic populations: a systematic review and meta-analysis', Infectious Diseases of Poverty, 13, http://dx.doi.org/10.1186/s40249-024-01185-5
    Journal articles | 2022
    Legrand N; McGregor S; Bull R; Bajis S; Valencia BM; Ronnachit A; Einsiedel L; Gessain A; Kaldor J; Martinello M, 2022, 'Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection', Clinical Microbiology Reviews, 35, http://dx.doi.org/10.1128/cmr.00078-21
  • Conference Presentations | 2026
    Legrand N; Martinello M; Thomas J; Gunathilake M; Hosking K; Tatipata N; Chen J; Boffa J; Kaldor J; McGregor S, 2026, 'Estimating syphilis incidence from routine laboratory testing data in the Northern Territory, 2010–2023', presented at Australasian HIV&AIDS and Australasian Sexual & Reproductive Health Conference, Melbourne, 14 September 2026 - 17 September 2026
    Reports | 2024
    McGregor S; Legrand N; Naruka E; Chacon GP, 2024, Review of current literature and evidence on Human T-Lymphotropic Virus Type 1 infection.: Kirby Institute; 2024., https://healthinfonet.ecu.edu.au/healthinfonet/getContent.php?linkid=720357&title=Review+of+current+literature+and+evidence+on+Human+T-Lymphotropic+Virus+Type+1+%28HTLV-1%29+infection&contentid=50524_1
    Reports | 2020
    Bajis S; Bull R; Causer L; Kaldor J; Legrand N; Martinello M; McGregor S; Naruka E; Ronnachitand A; Valencia Arroyo B; Low N, 2020, Human T-lymphotropic virus type 1: technical report, World Health Organization, Geneve, https://apps.who.int/iris/handle/10665/339773